Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00235937
Status:
COMPLETED
Last Update Posted:
2011-01-21
First Post:
2005-10-10
Brief Title:
Study on Pre-menopausal Patients With Advanced ER and PR BC Treated With Arimidex Plus Zoladex
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Open Phase II Trial Assessing the Objective Response Rate After Combination of Arimidex 1mg Per osDay and Zoladex 36 mg Sub CutMonthly as 1st Treatment for Premenopausal Receptor Positive Advanced or Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease Arimidex 1 Mg per day per os and Zoladex 36 Mg in injections under cutaneous once per month in subjects with breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| THR 0104233 C | None | None | None |